Bharat Biotech’s intranasal immunization gets approval for stage 2/3 preliminary

0

KEY STORY

  • Bharat Biotech’s BBV154 intranasal vaccine has become the first of its kind to receive the regulatory approval for Phase 2/3 trials, according to a release issued by the Ministry of Science and Technology on Friday.
  • “This is the first of its kind COVID-19 jab to undergo human clinical trials in India. BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine. The Company has in-licensed technology from Washington University in St Louis, USA,” said the release.
  • The development of the vaccine was supported by the Department of Biotechnology (DBT) and its PSU, Biotechnology Industry Research Assistance Council (BIRAC), the release stated.
  • As per information released by the Ministry Phase 1 Clinical trial has been completed in age groups ranging ≥18 to ≤60 years.

CONCLUSION

  • “The Company reports that the doses of the vaccine administered to healthy volunteers in the Phase I clinical trial, has been well tolerated. Previously, the vaccine was found to be safe, immunogenic and well tolerated in the pre-clinical toxicity studies. The vaccine was able to elicit high level of neutralizing antibodies in animal studies,” noted the release.
  • Renu Swarup, Secretary, DBT and Chairperson, BIRAC, said the department, through Mission COVID Suraksha, was committed to developing safe and efficacious COVID-19 vaccines.

LEAVE A REPLY

Please enter your comment!
Please enter your name here